BioSpace News Archive

Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders and rare diseases, announced it has been granted Orphan Drug Designation for SPG302 in amyotrophic lateral sclerosis by the U.S. Food and Drug Administration.

Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $35.0 million in term loans.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Carolyne Zimmermann as Chief Business Officer.

Celltrion Healthcare Canada Limited announced the launch of Remsima™ SC, the world’s first subcutaneous formulation of infliximab in Canada for the treatment of adult patients with rheumatoid arthritis.

Bruker Corporation announced the launch of the FluoroType SARS-CoV-2 varID Q assay – a quantitative LiquidArray® mid-plex PCR panel.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 Healthcare ESG Symposium on June 17, 2021, at 11:20 a.m. Eastern time.

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, announced its participation in the following U.S.-based virtual investor conferences in June

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study have been completed ahead of schedule.

ELEVATE-RR head-to-head trial in previously treated patients showed less cardiovascular toxicity and fewer discontinuations due to adverse events for CALQUENCE versus ibrutinib